http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101243043-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33f1ab36f411764219292bd1bdcd68c8
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C259-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C229-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D319-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C229-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D319-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C239-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-136
filingDate 2006-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2013-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8082e609716793e28fdb799353353889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e8e36c990a09f09851e70d5ea4a81c5
publicationDate 2013-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-101243043-B
titleOfInvention Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
abstract Therefore the present invention relates specifically to the compounds of general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising H, -CnH2n-1, a linear or branched alkyl group having from 1 to 6 carbon atoms, or together form an aromatic or aliphatic ring with 5 or 6 atoms; R3 is selected from -CO-CH3, -NHOH, -OH, -OR6 in which R6 is a linear or branched alkyl group having from 1 to 6 carbon atoms; R4 is selected from H, a linear or branched alkyl group having from 1 to 6 carbon atoms, phenyl, benzyl, -CF3 or -CF2CF3, vinyl or allyl;R5, R7, R8 are hydrogen atoms; or R3 and R4, R4 and R5, or R7 and R8 together form a ring, fused to the benzene, aromatic or aliphatic ring with 5 or 6 atoms comprising from 1 to 2 heteroatoms selected independently from the group comprising N, O. and use thereof in the medical field.
priorityDate 2005-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9531194-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005012280-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0102833-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02095393-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468036579

Total number of triples: 34.